A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Public ClinicalTrials.gov record NCT02205528. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin
Study identification
- NCT ID
- NCT02205528
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Interventions
- Liraglutide Drug
- Metformin Drug
- NNC0090-2746 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 17, 2014
- Primary completion
- Sep 14, 2015
- Completion
- Sep 14, 2015
- Last update posted
- Jul 20, 2020
2014 – 2015
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Chino | California | 91710 | — |
| Novo Nordisk Investigational Site | Hawaiian Gardens | California | 90716 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90057 | — |
| Novo Nordisk Investigational Site | Spring Valley | California | 91978 | — |
| Novo Nordisk Investigational Site | Hialeah | Florida | 33012 | — |
| Novo Nordisk Investigational Site | Port Orange | Florida | 32127 | — |
| Novo Nordisk Investigational Site | Sanford | Florida | 32771 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60607 | — |
| Novo Nordisk Investigational Site | Evanston | Illinois | 60201 | — |
| Novo Nordisk Investigational Site | Oxon Hill | Maryland | 20745 | — |
| Novo Nordisk Investigational Site | Berlin | New Jersey | 08009 | — |
| Novo Nordisk Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Novo Nordisk Investigational Site | Greensboro | North Carolina | 27408 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45227 | — |
| Novo Nordisk Investigational Site | Tulsa | Oklahoma | 74136 | — |
| Novo Nordisk Investigational Site | Eugene | Oregon | 97404 | — |
| Novo Nordisk Investigational Site | Knoxville | Tennessee | 37920 | — |
| Novo Nordisk Investigational Site | Corpus Christi | Texas | 78404 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77074 | — |
| Novo Nordisk Investigational Site | Manassas | Virginia | 20110 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02205528, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2020 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02205528 live on ClinicalTrials.gov.